The effect of tecar therapy in chronic pelvic pai

Phase 3

Recruiting

Conditions: chronic pelvic pain.
Pelvic and perineal pain
R10.2

Registration Number: IRCT20151020024621N9

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 44

Inclusion Criteria

Age greater than or equal to 18 years
Suffering from chronic pelvic pain (any pain that lasts more than 6 months and is in the area below the navel to the gluteal fold and causes functional problems for the patient)
Presence of at least one painful muscle point in the pelvic area (below the navel to the gluteal fold)
Age less than 60 years

Exclusion Criteria

Performing other conservative treatments during the study (oral medicine, manual therapy, physiotherapy, osteopathy, chiropractic, massage)
People undergoing chemotherapy or radiotherapy in the pelvic
Existence of oncological disease
pregnancy
pelvic surgery in the last 6 months
Suffering from fibromyalgia or chronic fatigue
Suffering from serious mental disorders
The presence of excessive sensitivity in the skin that may interfere with the treatment process.
Suffering from neuromuscular diseases
Diabetic people

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain will be checked according to the VAS score. This quantitative and subjective variable includes marking the degree of pain intensity in a straight horizontal line with a constant length of 10 cm. The extremes are defined as extreme limits of a parameter measured from left (worst) to right (best). Timepoint: The beginning of the study (before the start of the intervention), the end of 10 treatment sessions, 3 and 6 months after the end of the treatment. Method of measurement: Visual Analog Scale.

Secondary Outcome Measures

Name	Time	Method
Average quality of life score. Timepoint: Before starting the treatment, after 10 treatment sessions, 3 months after the end of the treatment. Method of measurement: Short Form Health (SF-12).;Average score of fear of movement. Timepoint: Before starting the treatment, after 10 treatment sessions, 3 months after the end of the treatment. Method of measurement: Tampa Scale of Kinesiophobia (a questionnaire designed to evaluate the fear of movement from different dimensions (belief in injury, avoidance of activity).